Oxford BioTherapeutics Partners with GSK in Multi-Target Cancer Drug Discovery Collaboration
Key Insights
Oxford BioTherapeutics (search) announced a multi-year strategic collaboration with GSK to discover novel antibody-based cancer therapeutics using OBT's proprietary OGAP-Verify platform.
The partnership leverages OBT's enhanced proteomics discovery platform to identify oncology targets with improved drug development attributes for potential first-in-class therapies.
OBT will receive an undisclosed upfront payment plus milestone payments and royalties, marking the company's second major pharma collaboration this year.
Oxford BioTherapeutics (search) (OBT), a clinical-stage oncology company, has entered into a multi-year, multi-target strategic collaboration with GSK to discover novel potentially first-in-class antibody-based therapeutics for cancer treatment. The partnership announced on December 10, 2025, represents OBT's second major pharmaceutical collaboration this year and validates the growing recognition of the company's proprietary discovery platform.
OGAP-Verify Platform Drives Target Discovery
The collaboration centers on OBT's recently enhanced proprietary OGAP-Verify discovery platform, which enables highly sensitive identification of oncology targets with improved attributes for drug development. The platform's enhanced sensitivity, specificity, and reliability is designed to significantly accelerate biopharma's capabilities to identify and validate human targets with robust scientific support.
Under the agreement terms, targets will be identified through the OGAP-Verify discovery platform and validated through joint research collaboration. GSK will drive any subsequent research, development, and commercialization efforts against these targets, while OBT will receive an undisclosed upfront payment and remain eligible for downstream milestone payments and royalties on net sales of resulting products.
Addressing Unmet Medical Needs
"T-cell engager therapeutics and antibody-drug conjugates have shown great promise, yet today only a small fraction of cancer patients are currently eligible for these treatments," said Christian Rohlff, PhD, Chief Executive Officer of Oxford BioTherapeutics (search). "We're driven by a patient-centric vision and excited to work with GSK to turn these discoveries into potential new treatment options that could reach many more people living with cancer."
Chris Austin, M.D., Senior Vice President of Research Technologies at GSK, emphasized the strategic value of the partnership: "Our collaboration with Oxford BioTherapeutics (search) enhances our in-house capabilities by integrating a best-in-class proteomics platform for oncology target identification, enabling us to work together to deliver impactful solutions for patients."
Clinical Pipeline and Validation
OBT's discovery capabilities have been validated through its clinical pipeline, with three programs originating from the OGAP technology now in clinical development in the US and Europe. The company's lead clinical program, OBT076, initiated expansion in a US clinical trial in 2021 for patients with advanced or refractory solid tumors, including gastric, bladder, ovarian and lung cancer, where CD205 is overexpressed.
The company's immuno-oncology discovery process provides unique insights into the cancer-immune cell synapse and has identified several novel monoclonal and bispecific antibody candidates for cancer therapies. OBT focuses on discovering and developing first-in-class antibody-based therapies, including bispecific antibodies and antibody drug conjugate therapeutics.
Strategic Partnership Portfolio
OBT's pipeline and development capabilities have been validated through multiple strategic partnerships with industry leaders including Roche, Boehringer Ingelheim, Zymeworks, Amgen, WuXi, Medarex (BMS), and Alere (Abbott). The GSK collaboration marks a significant expansion of the company's network of world-class pharmaceutical partners and reflects strong validation of the OGAP-Verify platform's potential to drive oncology innovation.